# Use of Impella RP Flex in Post-Heart Transplant Patients with RV Primary Graft Dysfunction

**Authors:** Ioana Dumitru, Jonathan DeWolf, Maria Sevillano, Leeandra Schnell, Hiram Bezerra, Debbie Rinde-Hoffman

PMC · DOI: 10.3390/biomedicines13061335 · 2025-05-29

## TL;DR

This study evaluates the use of the Impella RP Flex device to treat right ventricular dysfunction after heart transplants, finding it effective but noting significant bleeding and kidney issues.

## Contribution

The study provides clinical evidence on the safety and effectiveness of the Impella RP Flex for treating RV-PGD post-heart transplant.

## Key findings

- Five patients with RV-PGD showed recovery of right ventricular function after an average of 8.6 days of Impella RP Flex support.
- Common complications included hemolysis, bleeding, and acute kidney dysfunction requiring hemodialysis.
- No tricuspid valve injuries were observed, and one device showed transient biologic material ingestion during weaning.

## Abstract

Background: Right ventricular primary graft dysfunction (RV-PGD) is a rare but serious complication following heart transplantation, associated with a high morbidity and mortality. Temporary mechanical circulatory support is indicated when patients fail to respond to pharmacological therapy. This study aimed to evaluate the outcomes of patients with RV-PGD who received RV mechanical support with the Impella RP Flex device at our institution. Methods: Medical records of patients with RV-PGD supported by the Impella RP Flex device between December 2022 and March 2024 were reviewed retrospectively to assess survival, procedural complications, duration of support, and end organ dysfunction. Results: Of the 20 patients reviewed, 5 met the inclusion criteria. All five patients demonstrated recovery of RV function after a mean support duration of 8.6 ± 3.05 days. One pump showed transient evidence of biologic material ingestion during a weaning trial. No cases of tricuspid valve injury were observed. The most common complications were hemolysis, bleeding, and acute kidney dysfunction, with all patients requiring hemodialysis. Conclusions: Impella RP Flex support is safe and effective for managing primary and isolated RV-PGD without the need for additional blood oxygenation. However, bleeding complications requiring intervention remain a significant concern, and further evaluation of renal recovery is warranted.

## Full-text entities

- **Diseases:** end organ dysfunction (MESH:D009102), hemolysis (MESH:D006461), Primary Graft Dysfunction (MESH:D055031), RV-PGD (MESH:D018497), bleeding (MESH:D006470), acute kidney dysfunction (MESH:D058186), tricuspid valve injury (MESH:D014264)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC12190657